CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
E: InvestorRelations@csl.com.au
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29,904
CSL Ltd News & Analysis
stocks
Are investors too bearish on Australian equities?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,227.20 | 71.20 | -0.77% |
| CAC 40 | 8,216.58 | 22.60 | -0.27% |
| DAX 40 | 24,278.63 | 30.15 | -0.12% |
| Dow JONES (US) | 47,706.37 | 161.78 | 0.34% |
| FTSE 100 | 9,696.74 | 42.92 | 0.44% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,827.49 | 190.04 | 0.80% |
| Nikkei 225 | 51,258.42 | 1,039.24 | 2.07% |
| NZX 50 Index | 13,414.03 | 11.37 | 0.08% |
| S&P 500 | 6,890.89 | 15.73 | 0.23% |
| S&P/ASX 200 | 8,935.30 | 76.80 | -0.85% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |